Skip to content

Replimune Group REPL Debt-to-assets

Debt-to-assets at other companies

Amgen logo
AmgenAMGN
0.6×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
+0.5×
Immunome logo
ImmunomeIMNM
0.0×
CG Oncology logo
CG OncologyCGON
0.0×
Erasca, Inc. logo
Erasca, Inc.ERAS
0.1×0.0×

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Calculated from Replimune Group’s reported figures.

Based on the most recent quarter.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's debt-to-assets?
Replimune Group (REPL) reported debt-to-assets of 0.2× in Q4 2025.
How has Replimune Group's debt-to-assets changed year-over-year?
Replimune Group's debt-to-assets increased by 81.8% year-over-year, from 0.1× to 0.2×.
What is the long-term trend for Replimune Group's debt-to-assets?
Over 4 years (2021 to 2025), Replimune Group's debt-to-assets has grown at a 21.4% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.